Lakefront Biotherapeutics (LKFT) Shares Outstanding (Diluted Average) (2015 - 2025)

Lakefront Biotherapeutics (LKFT) has 11 years of Shares Outstanding (Diluted Average) data on file, last reported at $76.7 million in Q4 2025.

• Shares Outstanding (Diluted Average) for Q4 2025 came in at $76.7 million, up 8.93% year-over-year; the trailing twelve-month figure through Dec 2025 was $76.7 million (up 8.93% YoY), and the FY2025 annual result was $76.7 million, up 8.93% from the prior year.
• Shares Outstanding (Diluted Average) improved to $76.7 million in Q4 2025 per LKFT's latest filing, from $74.6 million in the prior quarter.
• Over five years, Shares Outstanding (Diluted Average) peaked at $76.7 million in Q4 2025 and troughed at $168.87 in Q1 2021.
• A 5-year average of $56.2 million and a median of $70.9 million in 2023 frame the typical range for Shares Outstanding (Diluted Average).
• On a YoY basis, Shares Outstanding (Diluted Average) climbed as much as 92905.3% in 2021 and fell as far as 99.26% in 2021.
• A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $74.9 million in 2021, then retreated by 10.54% to $67.0 million in 2022, then grew by 5.76% to $70.9 million in 2023, then dropped by 0.66% to $70.4 million in 2024, then grew by 8.93% to $76.7 million in 2025.
• Business Quant data shows LKFT's Shares Outstanding (Diluted Average) at $76.7 million in Q4 2025, $74.6 million in Q2 2025, and $70.4 million in Q4 2024.